Physician profile
Taryn D Silverstein
NPI 1215082102
$4,430.66
in general payments reported to CMS, 2019-2025
22 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $544 · 2021: $494 · 2022: $400 · 2023: $709 · 2024: $811 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545 · Education: $85.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,545.43 |
| Education | $85.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.07 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Qol Medical, LLC | $596.52 | 2019-2023 | Sucraid |
| Janssen Biotech, INC. | $571.65 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $459.51 | 2022-2025 | Entyvio, Gattex |
| Celgene Corporation | $360.56 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.94 | 2019-2025 | Xifaxan |
| Braintree Laboratories, INC. | $175.01 | 2019 | |
| Lilly USA, LLC | $154.82 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $78.10 | 2025 | Rezdiffra |
| Ardelyx, INC. | $56.38 | 2024 | Ibsrela |
| Celltrion USA INC. | $46.07 | 2024 | Zymfentra, Vegzelma |
| Amgen INC. | $45.45 | 2022-2023 | Avsola, Amjevita |
| Novo Nordisk INC | $42.53 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $38.00 | 2020-2021 | |
| Pfizer INC. | $35.15 | 2021-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $31.78 | 2019 | |
| Genzyme Corporation | $28.38 | 2025 | |
| Gilead Sciences, INC. | $25.59 | 2025 | |
| Nestle Healthcare Nutrition INC. | $19.89 | 2023 | |
| Redhill Biopharma INC. | $18.72 | 2020 | |
| Allergan, INC. | $16.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,608.20 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taryn Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.